Transgene Biotek Limited (TRABI.BO)
INR 7.34
(-0.53%)
INR 7.34
(-0.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.69 Million INR | -1406.46% |
| 2022 | -112.31 Thousand INR | -108.45% |
| 2021 | 1.32 Million INR | 22.25% |
| 2020 | 1.08 Million INR | 1069.67% |
| 2019 | -112.12 Thousand INR | -129.95% |
| 2018 | 374.34 Thousand INR | -46.16% |
| 2017 | 695.3 Thousand INR | 100.38% |
| 2016 | -182.02 Million INR | -10168.37% |
| 2015 | 1.8 Million INR | -38.41% |
| 2014 | 2.93 Million INR | -60.38% |
| 2013 | 7.4 Million INR | -5.56% |
| 2012 | 7.84 Million INR | -81.46% |
| 2011 | 42.3 Million INR | -11.48% |
| 2010 | 47.79 Million INR | 50.18% |
| 2009 | 31.82 Million INR | 0.09% |
| 2008 | 31.79 Million INR | 2.84% |
| 2007 | 30.91 Million INR | 84.28% |
| 2006 | 16.77 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 492 Thousand INR | 189.45% |
| 2023 FY | -1.69 Million INR | -1406.46% |
| 2023 Q2 | 448.56 Thousand INR | -54.94% |
| 2023 Q1 | 995.53 Thousand INR | 255.45% |
| 2023 Q4 | -550 Thousand INR | -0.36% |
| 2023 Q3 | -548 Thousand INR | -222.17% |
| 2022 FY | -112.31 Thousand INR | -108.45% |
| 2022 Q2 | -4894.00 INR | -100.9% |
| 2022 Q3 | -10.8 Thousand INR | -120.68% |
| 2022 Q1 | 543.64 Thousand INR | -64.64% |
| 2022 Q4 | -640.41 Thousand INR | -5829.8% |
| 2021 Q4 | 1.53 Million INR | 1258.13% |
| 2021 Q1 | -60.91 Thousand INR | 77.95% |
| 2021 FY | 1.32 Million INR | 22.25% |
| 2021 Q3 | -132.75 Thousand INR | -803.69% |
| 2021 Q2 | -14.69 Thousand INR | 75.89% |
| 2020 FY | 1.08 Million INR | 1069.67% |
| 2020 Q1 | -42.07 Thousand INR | -111.96% |
| 2020 Q2 | -95.26 Thousand INR | -126.41% |
| 2020 Q3 | 1.5 Million INR | 1675.38% |
| 2020 Q4 | -276.25 Thousand INR | -118.41% |
| 2019 FY | -112.12 Thousand INR | -129.95% |
| 2019 Q4 | 351.7 Thousand INR | 731.07% |
| 2019 Q3 | -55.73 Thousand INR | -745.71% |
| 2019 Q2 | -6590.00 INR | 98.36% |
| 2019 Q1 | -401.5 Thousand INR | 55.82% |
| 2018 Q4 | -908.74 Thousand INR | -627.26% |
| 2018 FY | 374.34 Thousand INR | -46.16% |
| 2018 Q3 | -124.95 Thousand INR | -551.97% |
| 2018 Q2 | -19.16 Thousand INR | -102.68% |
| 2018 Q1 | 714.34 Thousand INR | 0.0% |
| 2017 FY | 695.3 Thousand INR | 100.38% |
| 2016 FY | -182.02 Million INR | -10168.37% |
| 2016 Q4 | - INR | 0.0% |
| 2015 FY | 1.8 Million INR | -38.41% |
| 2015 Q4 | - INR | 0.0% |
| 2014 FY | 2.93 Million INR | -60.38% |
| 2013 FY | 7.4 Million INR | -5.56% |
| 2012 Q3 | 905 Thousand INR | -75.57% |
| 2012 Q2 | 3.7 Million INR | 5192.86% |
| 2012 Q1 | 70 Thousand INR | 0.0% |
| 2012 FY | 7.84 Million INR | -81.46% |
| 2012 Q4 | 3.17 Million INR | 250.37% |
| 2011 FY | 42.3 Million INR | -11.48% |
| 2010 FY | 47.79 Million INR | 50.18% |
| 2009 FY | 31.82 Million INR | 0.09% |
| 2008 FY | 31.79 Million INR | 2.84% |
| 2007 FY | 30.91 Million INR | 84.28% |
| 2006 FY | 16.77 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 10.46 Million INR | 116.174% |
| Biocon Limited | 91.73 Billion INR | 100.002% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | 100.054% |
| Concord Biotech Limited | 6.11 Billion INR | 100.028% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | 100.035% |
| FERMENTA BIOTECH LIMITED | 1.82 Billion INR | 100.093% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | 202.499% |
| Lyka Labs Limited | 145.95 Million INR | 101.159% |
| Panacea Biotec Limited | 1.35 Billion INR | 100.125% |
| SAMSRITA LABS LIMITED | -1.28 Million INR | -31.871% |
| Servoteach Industries Limited | - INR | Infinity% |
| SMS Lifesciences India Limited | 329.57 Million INR | 100.513% |
| Supriya Lifescience Limited | 2.65 Billion INR | 100.064% |
| Syngene International Limited | 12.43 Billion INR | 100.014% |
| TAKE Solutions Limited | 183.42 Million INR | 100.922% |
| Titan Biotech Limited | 884.66 Million INR | 100.191% |
| Vanta Bioscience Limited | 7.12 Million INR | 123.764% |